CA2140150A1 - Antigene du complexe majeur d'histocompatibilite, pour utilisation comme vaccin contre un virus associe a l'immunodeficience - Google Patents
Antigene du complexe majeur d'histocompatibilite, pour utilisation comme vaccin contre un virus associe a l'immunodeficienceInfo
- Publication number
- CA2140150A1 CA2140150A1 CA002140150A CA2140150A CA2140150A1 CA 2140150 A1 CA2140150 A1 CA 2140150A1 CA 002140150 A CA002140150 A CA 002140150A CA 2140150 A CA2140150 A CA 2140150A CA 2140150 A1 CA2140150 A1 CA 2140150A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- cells
- class
- virus
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 32
- 108091007433 antigens Proteins 0.000 title claims abstract description 32
- 102000036639 antigens Human genes 0.000 title claims abstract description 32
- 241000700605 Viruses Species 0.000 title claims abstract description 31
- 206010061598 Immunodeficiency Diseases 0.000 title claims abstract description 12
- 208000029462 Immunodeficiency disease Diseases 0.000 title claims abstract description 12
- 230000007813 immunodeficiency Effects 0.000 title claims abstract description 12
- 229960005486 vaccine Drugs 0.000 title claims abstract description 12
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims abstract description 18
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims abstract description 18
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 10
- 108010075704 HLA-A Antigens Proteins 0.000 claims abstract description 6
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 4
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims abstract description 4
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims abstract description 4
- 108010058607 HLA-B Antigens Proteins 0.000 claims abstract description 4
- 102000043129 MHC class I family Human genes 0.000 claims abstract description 4
- 108091054437 MHC class I family Proteins 0.000 claims abstract description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract description 3
- 102000006390 HLA-B Antigens Human genes 0.000 claims abstract 2
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 claims abstract 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 description 68
- 210000004027 cell Anatomy 0.000 description 52
- 241000713311 Simian immunodeficiency virus Species 0.000 description 21
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000009696 proliferative response Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108700005089 MHC Class I Genes Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000000521 hyperimmunizing effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229940124718 AIDS vaccine Drugs 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229910018626 Al(OH) Inorganic materials 0.000 description 1
- 102000010910 CD28 Antigens Human genes 0.000 description 1
- 108010062433 CD28 Antigens Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010014691 Lithostathine Proteins 0.000 description 1
- 102100027361 Lithostathine-1-alpha Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 description 1
- GVOIQSXBMLNCLC-UHFFFAOYSA-N OOOS Chemical compound OOOS GVOIQSXBMLNCLC-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 102100036851 Platelet glycoprotein IX Human genes 0.000 description 1
- 101710191888 Platelet glycoprotein IX Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 101000870331 Vasconcellea cundinamarcensis Cysteine proteinase 2 Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- -1 propylene glycol Chemical compound 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929214871A GB9214871D0 (en) | 1992-07-13 | 1992-07-13 | Vaccines |
| GB9214871.7 | 1992-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2140150A1 true CA2140150A1 (fr) | 1994-01-20 |
Family
ID=10718631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002140150A Abandoned CA2140150A1 (fr) | 1992-07-13 | 1993-07-13 | Antigene du complexe majeur d'histocompatibilite, pour utilisation comme vaccin contre un virus associe a l'immunodeficience |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0650369A1 (fr) |
| JP (1) | JPH07508984A (fr) |
| AU (1) | AU4576293A (fr) |
| CA (1) | CA2140150A1 (fr) |
| GB (1) | GB9214871D0 (fr) |
| WO (1) | WO1994001130A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1274592B (it) * | 1994-08-05 | 1997-07-18 | Angela Turiano | Composizione farmaceutica per la terapia tumorale contenente xenoantigeni |
| FR2735984B1 (fr) * | 1995-06-30 | 1997-09-19 | Inst Nat Sante Rech Med | Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic |
| EP1000628A1 (fr) * | 1998-09-28 | 2000-05-17 | Fondation Mondiale Recherche et Prevention SIDA | Utilisation de complexes antigènes de l'enveloppe de VIH et des antigènes HLA classe I comme vaccin contre le VIH |
| AU2005202644B2 (en) * | 1999-06-01 | 2009-03-05 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69124372T2 (de) * | 1990-05-10 | 1997-08-07 | Dana Farber Cancer Inst Inc | Erhöhung der assoziation exogener peptide mit mhci-molekülen auf zellen des immunsystems |
-
1992
- 1992-07-13 GB GB929214871A patent/GB9214871D0/en active Pending
-
1993
- 1993-07-13 JP JP6503132A patent/JPH07508984A/ja not_active Withdrawn
- 1993-07-13 AU AU45762/93A patent/AU4576293A/en not_active Abandoned
- 1993-07-13 WO PCT/GB1993/001459 patent/WO1994001130A1/fr not_active Application Discontinuation
- 1993-07-13 CA CA002140150A patent/CA2140150A1/fr not_active Abandoned
- 1993-07-13 EP EP93916056A patent/EP0650369A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB9214871D0 (en) | 1992-08-26 |
| EP0650369A1 (fr) | 1995-05-03 |
| JPH07508984A (ja) | 1995-10-05 |
| WO1994001130A1 (fr) | 1994-01-20 |
| AU4576293A (en) | 1994-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chan et al. | Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. | |
| EP0497883B1 (fr) | Compositions et leur utilisation pour le promotion de l'immunopotentialisation | |
| Johnson et al. | Superantigens: structure and relevance to human disease | |
| US6406696B1 (en) | Methods of stimulating the immune system with anti-CD3 antibodies | |
| Putkonen et al. | Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys | |
| Ward et al. | Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin | |
| GARDNER et al. | Passive immunization of rhesus macaques against SIV infection and disease | |
| WO1991004045A1 (fr) | Prophylaxie et therapie du syndrome d'immunodeficience acquise | |
| Zolla-Pazner et al. | Passive immunization for the prevention and treatment of HIV infection | |
| AU710626B2 (en) | Non-toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation process and pharmaceutical compositions comprising them | |
| AU2002317285B2 (en) | Use of polyclonal anti-HIV goat serum as a therapeutic agent | |
| WO1990014835A1 (fr) | Procede permettant de traiter le rhumatisme articulaire | |
| Härfast et al. | Immunoglobulin-independent natural cytotoxicity of Fc receptor-bearing human blood lymphocytes to mumps virus-infected target cells | |
| US5658569A (en) | Anti-HIV-1 neutralizing antibodies | |
| CA2140150A1 (fr) | Antigene du complexe majeur d'histocompatibilite, pour utilisation comme vaccin contre un virus associe a l'immunodeficience | |
| EP0762895B1 (fr) | Vaccin de synthese protegeant contre l'infection par le vih | |
| Gorse et al. | Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration | |
| Gardner et al. | Passive immunization of macaques against SIV infection | |
| Polyanskaya et al. | Anti-major histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection | |
| Brett et al. | Differential functional effects of a humanized anti‐CD4 antibody on resting and activated human T cells | |
| EP0423198B1 (fr) | Anticorps specifiques envers hiv 1 gp 48 | |
| KR19980702834A (ko) | 레트로바이러스 조절 단백질로부터 유래된 비독성 면역원, 항체, 그들의 제조 방법, 및 그들을 함유한 제약 조성물 | |
| WO1993014126A1 (fr) | Antigene de classe ii du complexe d'histocompatibilite majeure utilise dans un vaccin contre un virus d'immunodeficience | |
| Nanda | Preferential restriction of minor alloantigen-specific suppressor T cells to IE rather than IA molecules. | |
| Liew | Immunological Considerations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 19980713 |